Evidence map›Paper›PMID 40821443›Full record

ArticleMatter2025

Sustained exposure to multivalent antigen-decorated nanoparticles generates broad anti-coronavirus responses.

Julie Baillet, John H Klich, Ben S Ou, Emily L Meany, Jerry Yan, Theodora U J Bruun, Ashley Utz, Carolyn K Jons, Sebastien Lecommandoux, Eric A Appel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Matter, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julie BailletDepartment of Material Science and Engineering, Stanford University, Stanford, CA, 94305, USA.
John H KlichDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Ben S OuDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Emily L MeanyDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Jerry YanDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Theodora U J BruunSarafan ChEM-H, Stanford University, Stanford, CA, 94305, USA.
Ashley UtzStanford Biophysics Program, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Carolyn K JonsDepartment of Material Science and Engineering, Stanford University, Stanford, CA, 94305, USA.
Sebastien LecommandouxUniv. Bordeaux, CNRS, Bordeaux INP, LCPO, UMR 5629, F-33600 Pessac, France.
Eric A AppelDepartment of Material Science and Engineering, Stanford University, Stanford, CA, 94305, USA.

Funding

Graduate Training Program in BiotechnologyT32GM008412 · NIGMS · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 1991 to 2020
$5.5M
30-parameter FACSymphony A3 flow cytometer for Shared Resource LabS10OD026831 · OD · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2019 to 2019
$510k
Gates Foundation INV-027411NIGMS NIH HHS T32 GM008412NIH HHS S10 OD026831
6 · The paper itself

Abstract

The threat of future coronavirus pandemics requires developing effective vaccine technologies that provide broad and long-lasting protection against circulating and emerging strains. Here we report a multivalent liposomal hydrogel vaccine technology comprising the receptor binding domain (RBD) of up to four SARS and MERS coronavirus strains non-covalently displayed on the surface of the liposomes within the hydrogel structure. The multivalent presentation and sustained exposure of RBD antigens improved the potency, neutralizing activity, durability, and consistency of antibody responses across homologous and heterologous coronavirus strains in a naïve murine model. When administrated in animals pre-exposed to wild-type SARS-CoV-2 antigens, liposomal hydrogels elicited durable antibody responses against the homologous SARS and MERS strains for over six months and elicited neutralizing activity against the immune-evasive SARS-CoV-2 variant Omicron BA.4/BA.5. Overall, the tunable liposomal hydrogel platform we report here generates robust responses against diverse coronaviruses, supporting global efforts to respond to future viral outbreaks.

Indexed as

CoronavirusDrug DeliveryHydrogelsLiposomesVaccines

Identifiers

PMID40821443
PMCPMC12352413

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.